LMT 503
Alternative Names: LMT-503Latest Information Update: 26 Sep 2023
At a glance
- Originator Lmito Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 01 Mar 2023 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in Netherlands (PO) (NCT05659953)
- 04 Jan 2023 Lmito Therapeutics announces intention to submit IND application for Inflammatory bowel diseases
- 27 Dec 2022 Lmito Therapeutics plans a phase I pharmacokinetic trial for Inflammatory bowel diseases (In volunteers) in Netherlands March 2023 (PO) (NCT05659953)